Twice-daily cimetidine does not increase gastric bacterial flora

J. T. BOURNE*
B.Sc., M.D., M.R.C.P.

R. A. MOUNTFORD
M.D., M.R.C.P., F.R.C.R.

R. E. BARRY
B.Sc., M.D., F.R.C.P.

Department of Medicine, University of Bristol, Bristol Royal Infirmary, Bristol BS2 8HW

Summary

Thirty patients with peptic ulcer (20 duodenal, 10 gastric) underwent glucose-hydrogen (H_2) breath tests before and after 6 weeks treatment with cimetidine, 400 mg twice daily. For the group as a whole, basal breath H_2 and integrated H_2 output over a 2.5 hr test period was unchanged by cimetidine treatment. We conclude that there was no evidence of significant gastric bacterial colonization following twice daily cimetidine treatment.

KEY WORDS: duodenal ulcer, gastric ulcer, nitrosamine.

Introduction

Production of nitrosamines following bacterial overgrowth in the hypochlorhydric stomach may be a mechanism for potential carcinogenesis in patients on long-term cimetidine (Editorial, 1981). The extent and significance of such bacterial overgrowth is controversial. There is little doubt that bacterial numbers increase in the context of raised intragastric pH immediately following ingestion of cimetidine (Deane *et al.*, 1980; Ruddell *et al.*, 1980; Muscroft *et al.*, 1981a; Stockbrugger *et al.*, 1981). Doubt has been raised whether such bacteria are metabolically active or persist long enough to be of importance (Muscroft *et al.*, 1981b; Milton-Thompson *et al.*, 1982).

We have sought to assess bacterial colonization in patients receiving cimetidine using an accepted functional assay (Levitt and Ingelfinger, 1968; Metz *et al.*, 1976). Patients received twice daily cimetidine in a regime of proven efficacy (Kerr, 1981). Such regimes are likely to be adopted for patients receiving long-term treatment and who, in turn, are most at risk from potential carcinogenesis.

Patients and methods

Thirty patients (age range: 30-83 years, mean: 60) with endoscopically proven peptic ulcers (20 duode-

nal, 10 gastric) underwent a glucose-hydrogen (H_2) breath test before and after 6 weeks treatment with cimetidine, 400 mg twice daily taken at 10.00 p.m. and 8.00 a.m. No patient had received cimetidine or other histamine H_2 receptor antagonists before the study and poorly compliant patients were excluded. Patients fasted from mid-night for the glucose- H_2 breath test which commenced at 8.30 a.m. The morning dose of cimetidine was omitted. Four basal breath H_2 estimates were made at 15-min intervals using a Hoek Loos breath hydrogen analyser (Levitt and Ingelfinger, 1968). Fifty grams of glucose in 200 ml water was then administered by mouth. Breath H_2 was estimated serially at 15 min intervals for 2.5 hr. Basal breath H_2 and integrated H_2 output with respect to time (indicated by the area under the curve) were measured as an index of bacterial metabolic activity before and after cimetidine treatment. Significance was assessed by means of a paired *t*-test.

Results

For the group as a whole basal breath H_2 output was unchanged by cimetidine treatment (Table 1). Similarly no significant change was seen in the integrated H_2 output over the test period. No evidence of significant bacterial colonization following cimetidine treatment was therefore demonstrated. Before treatment basal H_2 levels in patients with duodenal ulcer (DU) were higher than in those with gastric ulcer (GU): DU 105 ± 25.5 ppm, GU 58 ± 5.9 ppm: ($P < 0.05$). This difference was lost after cimetidine treatment.

Discussion

There is considerable evidence of an increased gastric flora as a consequence of raised intragastric pH, immediately following cimetidine administration

*Present address: Department of Rheumatology, St Bartholomew's Hospital, London EC1A 7BE.

TABLE 1. Basal breath H_2 and integrated H_2 output (ppm) in 30 patients with duodenal (20) or gastric ulcer (10) before and after 6 weeks cimetidine 400 mg twice daily. (A) All ulcers combined (B) Groups expressed separately

	Pre-treatment		On cimetidine		P
	Mean	S.E.M.	Mean	S.E.M.	
(A)					
Basal breath H_2	89.7	17.5	81.7	9.2	NS
Integrated H_2 output	10.5	2.8	9.1	1.8	NS
(B)					
Basal breath H_2					
Duodenal	105.0	25.5	78.0	8.6	NS
Gastric	58.0	5.9	88.0	22.4	NS
Integrated H_2 output					
Duodenal	10.3	3.9	8.6	1.9	NS
Gastric	11.0	3.3	10.0	3.9	NS

Basal breath H_2 : duodenal vs gastric ulcer (a) pre-treatment $P < 0.05$, (b) on cimetidine $P = 0.318$ (NS); S.E.M. = standard error of mean; NS = not significant.

(Deane *et al.*, 1980; Ruddell *et al.*, 1980; Muscroft *et al.*, 1981a; Stockbrügger *et al.*, 1981). Important to any potential role in carcinogenesis is the metabolic activity of such bacteria and the length of time for which they maintain that activity in the stomach. For this reason we chose to study patients on a twice daily cimetidine regime which is of relevance where long-term maintenance therapy is contemplated. Patients were studied 10.5 hr after their last (evening) cimetidine dose in preference to immediately after their morning dose. Muscroft *et al.* (1981a) showed that of 41 patients taking cimetidine, 400 mg at night, 34% had significant bacteria in their aspirates 12–13 hr later, whilst Longstreth, Go and Malagelada (1976) found three out of six patients to be anacid 8 hr after a single 400 mg cimetidine dose.

Hydrogen is not produced by human metabolic processes but is released by the activity of gut flora on a glucose substrate. Since glucose is completely absorbed in the upper gastrointestinal tract without contact with colonic or ileal flora, breath hydrogen analysis following an oral glucose load provides a simple means of detecting metabolically active bacteria in the stomach and upper gastrointestinal tract. In 30 patients given cimetidine, 400 mg twice daily, no increase in bacterial activity was detected. Whilst the sensitivity of this technique has not been accurately established, it has nevertheless found an important place in clinical practice where evidence of upper gastrointestinal bacterial colonization has been sought (Metz *et al.*, 1976). Not all types of gut bacteria are detected by this technique (Metz *et al.*, 1976). However a very wide range of bacteria produce hydrogen during fermentation (Levitt and Ingelfinger, 1968). Our results make it unlikely that there is a large undetected reservoir of metabolically active nitrate-reducing bacteria in the upper gastrointestinal tract of these patients (Reed *et al.*, 1981).

The finding of high basal H_2 levels in untreated

DU patients compared with GU patients was unexpected. Muscroft *et al.* (1981a) analysed gastric aspirates from 51 untreated DU patients and found 88% to be sterile. Only two aspirates contained more than 10^6 organisms/ml. It is likely that elevated basal hydrogen was due to fermentation of carbohydrate in the colon (Levitt and Ingelfinger, 1968). An alternative explanation is that relief of pyloric oedema and improved gastric emptying resulted in diminished H_2 production in these patients following treatment.

Additional data are clearly required concerning the metabolic activity and carcinogenic potential of bacteria and their products in patients receiving cimetidine. Nevertheless, this study provides some assurance that such bacterial colonization does not appear to be prolonged or important in patients on maintenance regimes of this type.

Acknowledgments

We are grateful to Mrs R. Pratt for carrying out the glucose- H_2 breath tests.

References

- DEANE, S.A., YOUNGS, D.J., POXON, V.A. & KEIGHLEY, M.R.B. (1980) Cimetidine and gastric microflora. *British Journal of Surgery*, **67**, 371 (abstr).
- EDITORIAL (1981) Bacteria in the stomach. *Lancet*, **ii**, 906.
- KERR, G.D. (1981) Cimetidine: twice daily administration in duodenal ulcer—results of UK and Ireland multicentre study. In: *Cimetidine in the 80's*. (Ed. J. H. Baron), p. 9. Churchill Livingstone, London.
- LEVITT, M.D. & INGELFINGER, F.J. (1968) Hydrogen and methane production in man. *Annals of the New York Academy of Sciences*, **150**, 75.
- LONGSTRETH, G.F., GO, V.L.W. & MALAGELADA, J.R. (1976) Cimetidine suppression of nocturnal gastric secretion in active duodenal ulcer. *New England Journal of Medicine*, **294**, 801.
- METZ, G., GASSULL, M.A., DRASAR, B.S., JENKINS, D.J.A. & BLENDIS, L.M. (1976) Breath hydrogen test for small-intestinal bacterial colonization. *Lancet*, **i**, 668.
- MILTON-THOMPSON, G.J., LIGHTFOOT, N.F., AHMET, Z., HUNT,

- R.H., BARNARD, J., BAVIN, P.M.G., BRIMBLECOMBE, R.W., DARRIN, D.W., MOORE, P.J. & VINEY, N. (1982) Intragastric acidity, bacteria, nitrite and N-nitroso compounds before, during and after cimetidine treatment. *Lancet*, **i**, 1091.
- MUSCROFT, T.J., YOUNGS, D., BURDON, D.W. & KEIGHLEY, M.R.B. (1981a) Cimetidine and the potential risk of post-operative sepsis. *British Journal of Surgery*, **68**, 557.
- MUSCROFT, T.J., YOUNGS, D.J., BURDON, D.W. & KEIGHLEY, M.R.B. (1981b) Cimetidine is unlikely to increase formation of intragastric N-nitroso compounds in patients taking a normal diet. *Lancet*, **i**, 408.
- REED, P.I., SMITH, P.L.R., HAINES, K., HOUSE, F.R. & WALTERS, C.L. (1981) Gastric juice N-nitrosamines in health and gastroduodenal disease. *Lancet*, **ii**, 550.
- RUDDALL, W.S.J., AXON, A.T.R., FINDLEY, J.M., BARTHOLOMEW, B.A. & HILL, M.J. (1980) Effect of cimetidine on the gastric bacterial flora. *Lancet*, **i**, 672.
- STOCKBRÜGGER, R.W., EUGENIDES, N., BARTHOLOMEW, B., WALTERS, C.L., THOMPSON, R.E.M., HILL, M.J. & COTTON, P.B. (1981) Cimetidine-treatment intragastric bacterial overgrowth and its consequences. *Gastroenterology*, **80**, 1295, (abstr).

(Accepted 13 December 1983)